Skip to main content

AAN.com

Articles

November 2, 2009

The heritability and genetics of frontotemporal lobar degeneration

J. D. Rohrer, MRCP, R. Guerreiro, MS, J. Vandrovcova, PhD, J. Uphill, BSc, D. Reiman, J. Beck, BSc, A. M. Isaacs, DPhil, … Show All … , A. Authier, MSc, R. Ferrari, BSc, N. C. Fox, MD, FRCP, I.R.A. Mackenzie, PhD, J. D. Warren, PhD, FRACP, R. de Silva, DPhil, J. Holton, PhD, T. Revesz, MD, J. Hardy, PhD, S. Mead, PhD, MRCP, and M. N. Rossor, MD, FRCPAuthors Info & Affiliations

November 3, 2009 issue

73 (18) 1451-1456

https://doi.org/10.1212/WNL.0b013e3181bf997a

Abstract

Background: Frontotemporal lobar degeneration (FTLD) is a genetically and pathologically heterogeneous neurodegenerative disorder.

Methods: We collected blood samples from a cohort of 225 patients with a diagnosis within the FTLD spectrum and examined the heritability of FTLD by giving each patient a family history score, from 1 (a clear autosomal dominant history of FTLD) through to 4 (no family history of dementia). We also looked for mutations in each of the 5 disease-causing genes (MAPT, GRN, VCP, CHMP2B, and TARDP) and the FUS gene, known to cause motor neuron disease.

Results: A total of 41.8% of patients had some family history (score of 1, 2, 3, or 3.5), although only 10.2% had a clear autosomal dominant history (score of 1). Heritability varied across the different clinical subtypes of FTLD with the behavioral variant being the most heritable and frontotemporal dementia–motor neuron disease and the language syndromes (particularly semantic dementia) the least heritable. Mutations were found in MAPT (8.9% of the cohort) and GRN (8.4%) but not in any of the other genes. Of the remaining patients without mutations but with a strong family history, 7 had pathologic confirmation, falling into 2 groups: type 3 FTLD-TDP without GRN mutations (6) and FTLD-UPS (1).

Conclusion: These findings show that frontotemporal lobar degeneration (FTLD) is a highly heritable disorder but heritability varies between the different syndromes. Furthermore, while MAPT and GRN mutations account for a substantial proportion of familial cases, there are other genes yet to be discovered, particularly in patients with type 3 FTLD-TDP without a GRN mutation.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (rohner_73-18-1451.pdf)

Download
97.16 KB

REFERENCES

1.

Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 2007;114:5–22.

2.

Mackenzie IR, Rademakers R. The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics 2007;8:237–248.

3.

Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol 2004;55:335–346.

4.

Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology 2008;71:1227–1234.

5.

Kertesz A, Davidson W, Munoz DG. Clinical and pathological overlap between frontotemporal dementia, primary progressive aphasia and corticobasal degeneration: The Pick complex. Dement Geriatr Cogn Disord 1999;10:46–49.

6.

Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002;59:1077–1079.

7.

Chow TW, Miller BL, Hayashi VN, Geschwind DH. Inheritance of frontotemporal dementia. Arch Neurol 1999;56:817–822.

8.

Benajiba L, Le Ber I, Camuzat A, et al. TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol 2009;65:470–473.

9.

Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol 2009;117:15–18.

10.

Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546–1554.

11.

Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54 suppl 5:S15–S19.

12.

Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.

13.

Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 2005;65:1817–1819.

14.

Beck J, Rohrer JD, Campbell T, et al. A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 2008;131(Pt 3):706–720.

15.

Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009 27;323:1208–1211.

16.

Kwiatkowski TJ, Jr., Bosco DA, Leclerc AL, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009;323:1205–1208.

17.

Janssen JC, Warrington EK, Morris HR, et al. Clinical features of frontotemporal dementia due to the intronic tau 10(+16) mutation. Neurology 2002;58:1161–1168.

18.

Spillantini MG, Yoshida H, Rizzini C, et al. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol 2000;48:939–943.

19.

Rohrer JD, Beck J, Warren JD, et al. Corticobasal syndrome associated with a novel 1048_1049insG progranulin mutation. JNNP 2009 (in press).

20.

Snowden J, Neary D, Mann D. Frontotemporal lobar degeneration: clinical and pathological relationships. Acta Neuropathol 2007;114:31–38.

21.

Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008;63:709–719.

22.

Houlden H, Baker M, Adamson J, et al. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia. Ann Neurol 1999;46:243–248.

23.

Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003;126:2016–2022.

24.

Stanford PM, Brooks WS, Teber ET, et al. Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol 2004;251:1098–1104.

25.

Signorini S, Ghidoni R, Barbiero L, et al. Prevalence of pathogenic mutations in an Italian clinical series of patients with familial dementia. Curr Alzheimer Res 2004;1:215–218.

26.

Cruts M, Gijselinck I, van der Zee J, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 2006;442:920–924.

27.

Gass J, Cannon A, Mackenzie IR, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 2006;15:2988–3001.

28.

Le Ber I, van der Zee J, Hannequin D, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 2007;28:846–855.

29.

Pickering-Brown SM, Rollinson S, Du Plessis D, et al. Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 2008;131:721–731.

30.

Borroni B, Archetti S, Alberici A, et al. Progranulin genetic variations in frontotemporal lobar degeneration: evidence for low mutation frequency in an Italian clinical series. Neurogenetics 2008;9:197–205.

31.

Benussi L, Ghidoni R, Pegoiani E, et al. Progranulin Leu271LeufsX10 is one of the most common FTLD and CBS associated mutations worldwide. Neurobiol Dis 2009;33:379–385.

32.

Pickering-Brown S, Baker M, Bird T, et al. Evidence of a founder effect in families with frontotemporal dementia that harbor the tau +16 splice mutation. Am J Med Genet B Neuropsychiatr Genet 2004;125B:79–82.

33.

Seelaar H, Kamphorst W, Rosso SM, et al. Distinct genetic forms of frontotemporal dementia. Neurology 2008;71:1220–1226.

34.

Le Ber I, Camuzat A, Berger E, et al. Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology 2009;72:1669–1676.

35.

Mackenzie IR, Foti D, Woulfe J, Hurwitz TA. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions Brain 2008;131:1282–1293.

36.

Roeber S, Mackenzie IR, Kretzschmar HA, Neumann M. TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol 2008;116:147–157.

37.

Geser F, Martinez-Lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009;66:180–189.

38.

Josephs KA, Ahmed Z, Katsuse O, et al. Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol 2007;66:142–151.

39.

Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol Epub 2009 May 20.

Information & Authors

Information

Published In

Neurology^®

Volume 73 • Number 18 • November 3, 2009

Pages: 1451-1456

PubMed: 19884572

Copyright

© 2009.

Publication History

Published online: November 2, 2009

Published in print: November 3, 2009

Permissions

Request permissions for this article.

Request Permissions

Notes

Authors

Affiliations & Disclosures

J. D. Rohrer, MRCP

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

R. Guerreiro, MS

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

J. Vandrovcova, PhD

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

J. Uphill, BSc

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

D. Reiman

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

J. Beck, BSc

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

A. M. Isaacs, DPhil

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

A. Authier, MSc

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

R. Ferrari, BSc

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

N. C. Fox, MD, FRCP

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

I.R.A. Mackenzie, PhD

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

J. D. Warren, PhD, FRACP

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

R. de Silva, DPhil

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

J. Holton, PhD

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

T. Revesz, MD

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

J. Hardy, PhD

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

S. Mead, PhD, MRCP

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

M. N. Rossor, MD, FRCP

From the Dementia Research Centre (J.D.R., N.C.F., J.D.W., M.N.R.) and MRC Prion Unit (J.U., D.R., J.B., A.M.I., A.A., S.M.), Department of Neurodegenerative Disease, Reta Lila Weston Institute (R.F., J.H.), and Queen Square Brain Bank (J.V., R.d.S., J.H., T.R.), Department of Molecular Neuroscience, UCL Institute of Neurology, University College London, Queen Square, London, UK; Texas Tech University (R.F.), Health Sciences Center, Department of Internal Medicine, Lubbock, TX; Laboratory of Neurogenetics (R.G.), National Institute of Aging, National Institutes of Health, Bethesda, MD; Center for Neuroscience and Cell Biology (R.G.), University of Coimbra, Coimbra, Portugal; and Department of Pathology and Laboratory Medicine (I.R.A.M.), Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada.

View all articles by this author

Notes

Address correspondence and reprint requests to Professor Martin N. Rossor, Dementia Research Centre, Institute of Neurology, Queen Square, London WC1N 3BG, UK [email protected]

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By

- Marina Buciuc,
- Keith A. Josephs,
Other Tau-Related Parkinsonisms, International Compendium of Movement Disorders, (403-413), (2025).https://doi.org/10.1017/9781108989855.035
Crossref
- Russell P. Sawyer,
- Sarah Doran,
- Bruce L. Miller,
Frontotemporal dementia, Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease, (35-57), (2025).https://doi.org/10.1016/B978-0-443-19176-3.00032-7
Crossref
- Hossam Tharwat Ali,
- Idris Sula,
- Ahmed Elrefaey,
- Yara Ashour,
- Mennatullah Mohamed Eltaras,
- Haya Mohamed,
- Mostafa Meshref,
Gene therapy in neurodegenerative disorders, Essential Guide to Neurodegenerative Disorders, (631-654), (2025).https://doi.org/10.1016/B978-0-443-15702-8.00036-1
Crossref
- Kristin Schaffer Mendez,
- Maya L. Henry,
Primary progressive aphasia, Encyclopedia of the Human Brain, (486-500), (2025).https://doi.org/10.1016/B978-0-12-820480-1.00125-X
Crossref
- Neil Fahy,
- Oliver S. Hayes,
- Caroline V. Greaves,
- Sophie E. Goldsmith,
- Emilie V. Brotherhood,
- Jonathan D. Rohrer,
- Emma Harding,
- Joshua Stott,
The experience of “at‐risk” status for familial frontotemporal dementia (fFTD) and its impact on reproductive decision‐making: A qualitative study, Journal of Genetic Counseling, 34, 1, (2025).https://doi.org/10.1002/jgc4.2000
Crossref
- Antonio Longobardi,
- Sonia Bellini,
- Roland Nicsanu,
- Andrea Pilotto,
- Andrea Geviti,
- Alessandro Facconi,
- Chiara Tolassi,
- Ilenia Libri,
- Claudia Saraceno,
- Silvia Fostinelli,
- Barbara Borroni,
- Alessandro Padovani,
- Giuliano Binetti,
- Roberta Ghidoni,
Unveiling New Genetic Variants Associated with Age at Onset in Alzheimer’s Disease and Frontotemporal Lobar Degeneration Due to C9orf72 Repeat Expansions, International Journal of Molecular Sciences, 25, 13, (7457), (2024).https://doi.org/10.3390/ijms25137457
Crossref
- Claudia Saraceno,
- Lorenzo Pagano,
- Valentina Laganà,
- Andrea Geviti,
- Silvia Bagnoli,
- Assunta Ingannato,
- Salvatore Mazzeo,
- Antonio Longobardi,
- Silvia Fostinelli,
- Sonia Bellini,
- Alberto Montesanto,
- Giuliano Binetti,
- Raffaele Maletta,
- Benedetta Nacmias,
- Roberta Ghidoni,
Mutational Landscape of Alzheimer’s Disease and Frontotemporal Dementia: Regional Variances in Northern, Central, and Southern Italy, International Journal of Molecular Sciences, 25, 13, (7035), (2024).https://doi.org/10.3390/ijms25137035
Crossref
- Xinxin Chen,
- Yin Chen,
- Biyu Ni,
- Cheng Huang,
Research trends and hotspots for frontotemporal dementia from 2000 to 2022: a bibliometric analysis, Frontiers in Neurology, 15, (2024).https://doi.org/10.3389/fneur.2024.1399600
Crossref
- Francesca Malerba,
- Rita Florio,
- Ivan Arisi,
- Chiara Zecca,
- Maria Teresa Dell’Abate,
- Giancarlo Logroscino,
- Antonino Cattaneo,
Cerebrospinal fluid level of proNGF as potential diagnostic biomarker in patients with frontotemporal dementia, Frontiers in Aging Neuroscience, 15, (2024).https://doi.org/10.3389/fnagi.2023.1298307
Crossref
- Moira Ek,
- Johan Nilvebrant,
- Per-Åke Nygren,
- Stefan Ståhl,
- Hanna Lindberg,
- John Löfblom,
An anti-sortilin affibody-peptide fusion inhibits sortilin-mediated progranulin degradation, Frontiers in Immunology, 15, (2024).https://doi.org/10.3389/fimmu.2024.1437886
Crossref
See more

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login

Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
[email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

advertisement

Impact Factor

We are pleased to announce that Neurology^® was awarded a new Impact Factor of 8.4. Explore our latest research and articles and join our community of distinguished authors by submitting your work .

Open Review Pilot Project

Explore peer reviews, author responses, and editor comments on selected articles.

Learn More

Letters to the Editor

The Letters section represents an opportunity for ongoing author debate and post-publication peer review. View our submission guidelines for Letters to the Editor before submitting your comment.

Submit a Letter for this article

View full text|Download PDF